NASDAQ:EKSO

Ekso Bionics - EKSO Stock Forecast, Price & News

$1.27

-0.06 (-4.50%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.27
▼
$1.37
50-Day Range: $1.04
▼
$1.70
52-Week Range: $1.03
▼
$3.49

Volume: 43,613 shs
Average Volume: 50,808 shs
Market Capitalization: $16.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Ekso Bionics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 607.2% Upside
$9.00 Price Target
Short Interest: Healthy
0.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.11
Based on 4 Articles This Week
Insider Trading: Selling Shares
$33,677 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.04) to ($0.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

255th out of 1,027 stocks

General Industrial Machinery, Industry

3rd out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
Ekso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Ekso Bionics has a forecasted upside of 607.2% from its current price of $1.27.
Amount of Analyst Coverage
Ekso Bionics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.42% of the float of Ekso Bionics has been sold short.
Short Interest Ratio / Days to Cover
Ekso Bionics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ekso Bionics has recently decreased by 20.33%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ekso Bionics does not currently pay a dividend.
Dividend Growth
Ekso Bionics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EKSO.

1.6

News and Social Media Coverage

News Sentiment
Ekso Bionics has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Ekso Bionics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for EKSO on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ekso Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,677.00 in company stock.
Percentage Held by Insiders
Only 3.05% of the stock of Ekso Bionics is held by insiders.
Percentage Held by Institutions
Only 12.47% of the stock of Ekso Bionics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ekso Bionics are expected to grow in the coming year, from ($1.04) to ($0.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ekso Bionics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ekso Bionics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ekso Bionics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Stock News Headlines

December 8, 2022 | americanbankingnews.com

Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

December 5, 2022 | finance.yahoo.com

Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

December 2, 2022 | marketwatch.com

Robotic Exoskeletons Market | New Business Strategies And Forecast By 2028 with Top Countries Data

November 30, 2022 | americanbankingnews.com

Ekso Bionics (NASDAQ:EKSO) Receives New Coverage from Analysts at StockNews.com

November 27, 2022 | marketwatch.com

Socially Assistive Healthcare Assistive Robot Market 2022 : Trends, Industry Structure, Development, Demographics, Developing Factors By 2028

November 22, 2022 | marketwatch.com

Exoskeleton Market Size 2022 Global Analysis Report by Top Companies, Trends, Growth Factors, Detail Business Development and Forecast to 2026

November 14, 2022 | marketwatch.com

Bionic Exoskeletons Sales Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028

November 9, 2022 | finance.yahoo.com

Ekso Bionics Holdings Third Quarter 2022 Earnings: Misses Expectations

November 8, 2022 | marketwatch.com

Artificial Organ And Bionics Market Analysis Report 2022 Along with Statistics Figures, Forecasts till 2025

November 6, 2022 | seekingalpha.com

Ekso Bionics Holdings, Inc. (EKSO) Q3 2022 Earnings Call Transcript

November 4, 2022 | finance.yahoo.com

Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates

November 3, 2022 | finance.yahoo.com

Ekso Bionics Reports Third Quarter 2022 Results

November 2, 2022 | msn.com

Preview: Ekso Bionics Holdings's Earnings

November 2, 2022 | benzinga.com

Global Exoskeleton Market Size to Gain USD 3,340 million by 2026 Says MarketsandMarkets

November 2, 2022 | marketwatch.com

Noninvasive Radio Surgery Robot Market is Booming Worldwide to Show Significant Growth over the Forecast 2022 to 2028

October 27, 2022 | finance.yahoo.com

Ekso Bionics to Report Third Quarter 2022 Financial Results on November 3, 2022

October 12, 2022 | marketwatch.com

Wearable Robotic Exoskeleton Market Size and Growth Comprehend by Product Revenue, Growth Rate, Production Capacity Analysis and Forecast to 2028

October 11, 2022 | marketwatch.com

Bionic Exoskeletons Market 2022 Company Challenges, Latest Advancements, Growth Prediction, and Forecast by 2028 | 127 Pages Report

October 7, 2022 | marketwatch.com

Global Wearable Medical Robot Market Size and Outlook 2022 by Classification, Market Trend Analysis, Threats and Forecast till 2028 Research Report

October 4, 2022 | marketwatch.com

Rehabilitation Healthcare Assistive Robot Market Growth Analysis Report 2022 to 2029 | Barrett Technology, Cyberdyne, Ekso Bionics, Gait Tronics

September 29, 2022 | bizjournals.com

A dad turned his daughter's diagnosis into a bionic clothing company that will ship its first product yet this year

September 24, 2022 | finance.yahoo.com

Ekso Bionics Holdings, Inc. (EKSO)

September 22, 2022 | marketwatch.com

Exoskeleton Systems Market with Strong Focus on Industry Size, by Financial Highlights, Market Segments, Growth Rate, Revenue, and Forecast to 2028

September 20, 2022 | marketwatch.com

Medical Bionic Implants Market Share, Size, Growth, Future Trends, Key Players and Industry Analysis 2022-2028

September 15, 2022 | marketwatch.com

Gait Trainer Market include 91 Pages-Global Market Growth in CAGR value, New Trends, COVID-19 Impact, SWOT Analysis and Forecast 2022 to 2028

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Company Calendar

Last Earnings: 11/01/2021
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: General industrial machinery,
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EKSO
Previous Symbol: OTCMKTS:EKSOD
CUSIP: N/A
CIK: 1549084
Web: www.eksobionics.com
Phone: (510) 984-1761
Fax: 510-927-2647
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +607.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,760,000.00
Net Margins: -109.88%
Pretax Margin: -109.88%
Return on Equity: -45.07%
Return on Assets: -34.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.68
Quick Ratio: 4.23

Sales & Book Value

Annual Sales: $11.25 million
Price / Sales: 1.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.94 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 13,140,000
Free Float: 12,741,000
Market Cap: $16.72 million
Optionable: Not Optionable
Beta: 1.59

Key Executives

Mr. Steven A. Sherman (Age 76)
Chairman & CEO
Comp: $100k

Mr. Scott W. Davis (Age 52)
Pres & COO

Mr. Jerome Wong (Age 48)
Corp. Controller, Corp. Sec. & CFO

Ms. Rachael Anderson
Global Director of Marketing & Strategic Growth

Mr. Anthony Pratt
VP of Sales

Ms. Ann Cookson
HR Director

Ms. Foon Lim Chwee
Pres of APAC

Mr. Jason C. Jones
Sr. VP of Product Devel.

Mr. Stephan Aderhold
Sr. VP & GM of EMEA

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EKSO Stock - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings or view top-rated stocks.
What is Ekso Bionics' stock price forecast for 2023?: 1 analysts have issued 12-month price objectives for Ekso Bionics' stock. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 607.2% from the stock's current price.
View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts.
How have EKSO shares performed in 2022?: Ekso Bionics' stock was trading at $2.65 at the beginning of the year. Since then, EKSO stock has decreased by 52.0% and is now trading at $1.2726.
View the best growth stocks for 2022 here.
Are investors shorting Ekso Bionics?: Ekso Bionics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 49,000 shares, a decrease of 20.3% from the October 31st total of 61,500 shares. Based on an average daily trading volume, of 30,100 shares, the short-interest ratio is presently 1.6 days. Approximately 0.4% of the shares of the stock are sold short.
View Ekso Bionics' Short Interest.
When is Ekso Bionics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EKSO earnings forecast.
How were Ekso Bionics' earnings last quarter?: Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.58 million. Ekso Bionics had a negative net margin of 109.88% and a negative trailing twelve-month return on equity of 45.07%. During the same period last year, the business posted ($0.52) earnings per share.

When did Ekso Bionics' stock split?: Ekso Bionics shares reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of Ekso Bionics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include OrganiGram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).
What is Ekso Bionics' stock symbol?: Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."
Who are Ekso Bionics' major shareholders?: Ekso Bionics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (2.43%), Citadel Advisors LLC (0.00%), Strategic Wealth Investment Group LLC (0.17%) and Dimensional Fund Advisors LP (0.14%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends.
How do I buy shares of Ekso Bionics?: Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ekso Bionics' stock price today?: One share of EKSO stock can currently be purchased for approximately $1.27.
How much money does Ekso Bionics make?: Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $16.72 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact Ekso Bionics?: Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.

This page (NASDAQ:EKSO) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial